- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00365144
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
A Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Metastatic Gemcitabine-Refractory Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with metastatic pancreatic cancer that did not respond to previous treatment with gemcitabine.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Evaluate the 6-month overall survival rate in patients with gemcitabine hydrochloride-refractory metastatic pancreatic cancer treated with bevacizumab and erlotinib hydrochloride.
- Determine the safety and toxicity of this regimen in these patients.
Secondary
- Evaluate the objective response rate in these patients.
- Evaluate time to tumor progression in these patients.
- Determine the efficacy of this regimen, in terms of the proportion of patients with ≥ 50% decline in carbohydrate antigen 19-9, also called cancer antigen 19-9 (CA19-9) biomarker, in these patients.
- Obtain sequential measurements of circulating tumor cells (micrometastases) and endothelial cells in serum and correlate these variables with clinical outcomes (in patients enrolled in UCSF site only).
OUTLINE: This is an open-label, nonrandomized, multicenter study.
Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline and periodically during study for biomarker/laboratory analysis, including the CA19-9 biomarker. Circulating tumor micrometastases and endothelial cells are also measured in patients enrolled in University of California San Francisco (UCSF) site.
After completion of study treatment, patients are followed at 30 days and at 6 months.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed adenocarcinoma of the pancreas
Documented extrapancreatic metastases
- Radiographically measurable disease not required
Gemcitabine hydrochloride-refractory disease
Has undergone 1-3 prior therapies for locally advanced or metastatic disease with ≥ 1 regimen containing gemcitabine hydrochloride (alone or in combination with other agents)
- Treatment given in the adjuvant setting (radiotherapy and/or chemotherapy, given either concurrently or systemically) does not count as prior therapy as long as progressive disease occurs > 6 months after completion of treatment
- No central nervous system (CNS) or brain metastases
PATIENT CHARACTERISTICS:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- International Normalized Ratio (INR) ≤ 1.5 (except in patients receiving full-dose warfarin)
- Bilirubin ≤ 2.0 mg/dL
- Creatinine ≤ 2.0 mg/dL
- AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if documented liver metastases)
- Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
- No contact lense use during and for 14 days after completion of study treatment
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
- No history of other disease, metabolic dysfunction, or physical examination or clinical laboratory finding that contraindicates use of an investigational drug or precludes study compliance
No history of serious systemic disease, including any of the following:
- Myocardial infarction within the past 6 months
- Stroke within the past 6 months
- Uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg on medication)
- Unstable angina
- New York Heart Association class II-IV congestive heart failure
Unstable symptomatic arrhythmia requiring medication
- Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- Peripheral vascular disease ≥ grade 2
- No significant traumatic injury within the past 28 days
- No proteinuria (defined as urine protein:creatinine ratio ≥ 1.0 at screening)
- No clinically significant impairment of renal function
- No serious, nonhealing wound, ulcer, or bone fracture
- No evidence of bleeding diathesis or coagulopathy
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
PRIOR CONCURRENT THERAPY:
- More than 28 days since prior major surgery or open biopsy
- More than 7 days since prior fine-needle aspiration or core biopsy
No prior antiangiogenesis agent (e.g., bevacizumab or an oral vascular endothelial growth factor receptor small molecule inhibitor) given together with an agent that disrupts epidermal growth factor receptor signaling (e.g., cetuximab or erlotinib hydrochloride) for locally advanced or metastatic pancreatic cancer
- Prior treatment with either one of the above alone allowed
- More than 4 weeks since prior and no concurrent participation in another clinical trial
- No other concurrent antineoplastic or antitumor agents, including chemotherapy, radiotherapy, immunotherapy, or hormonal anticancer therapy
- No concurrent major surgery
- No other concurrent investigational agents
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Bevacizumab Plus Erlotinib Hydrochloride
A treatment cycle is 21 days: bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival Rate at 6 Months
Tidsramme: 6 months
|
Number of participants alive at 6 months
|
6 months
|
Safety and Toxicity
Tidsramme: 21 weeks
|
Treatment associated toxicities.
Adverse event assessments were performed on day 1 of each treatment cycle and at the end of treatment; the longest duration of treatment was 7 cycles (x 3 weeks)
|
21 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective Response as Measured by RECIST Criteria
Tidsramme: 21 weeks
|
Participants experiencing objecting response, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
21 weeks
|
Time to Tumor Progression
Tidsramme: from initial therapy to the first objective documentation of tumor progression
|
Time to tumor progression (TTP) was defined as the time from initial therapy to the first objective documentation of tumor progression (for patients with measurable disease) or to the data of death, if death was ascribed to progression of disease.
|
from initial therapy to the first objective documentation of tumor progression
|
Proportion of Patients With ≥ 25% Decline in Serum CA19-9 Biomarker
Tidsramme: 21 weeks
|
21 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Andrew Ko, MD, University of California, San Francisco
Publikationer og nyttige links
Generelle publikationer
- Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7. doi: 10.1007/s00280-010-1257-5. Epub 2010 Feb 4.
- Ko AH, Dito E, Schillinger B, et al.: A phase II study of bevacizumab (BEV) and erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic adenocarcinoma of the pancreas (PanCa). [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-187, 2007.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Sygdomme i det endokrine system
- Neoplasmer i fordøjelsessystemet
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Bugspytkirtel neoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Proteinkinasehæmmere
- Erlotinib hydrochlorid
- Bevacizumab
Andre undersøgelses-id-numre
- 054511
- UCSF-054511
- UCSF-H12191-28233-01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kræft i bugspytkirtlen
-
Tianjin Medical University Cancer Institute and...Ikke rekrutterer endnuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForenede Stater
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Washington University School of MedicineUniversity of Oklahoma Medical Center; Northwestern University Chicago... og andre samarbejdspartnereAfsluttet
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaHolland
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbejdspartnereRekrutteringKræft i bugspytkirtlen | PDAC - Pancreatic Ductal AdenocarcinomaDet Forenede Kongerige
-
Andrei IagaruIkke længere tilgængeligCarcinoide tumorer | Islet Cell (Pancreatic NET) | Andre neuroendokrine tumorerForenede Stater
-
Chinese PLA General HospitalRekrutteringBugspytkirtel neoplasmer | Kræft i bugspytkirtlen | Bugspytkirtelkræft | PDAC - Pancreatic Ductal AdenocarcinomaKina
Kliniske forsøg med laboratoriebiomarkøranalyse
-
Liao Jian AnRekrutteringHoved- og halskræftTaiwan
-
Fondation LenvalTrukket tilbage
-
Progenity, Inc.AfsluttetDowns syndrom | Aneuploidi | DiGeorges syndrom | Turners syndrom | Klinefelters syndrom | Kromosom sletning | Edwards syndrom | Patau syndromForenede Stater
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig indsatsItalien
-
Oregon Health and Science University4DMedicalTilmelding efter invitationLungesygdomme | KOL | Luftvejssygdom | DyspnøForenede Stater
-
IRCCS Eugenio MedeaRekrutteringCerebral Parese | Erhvervet hjerneskadeItalien
-
Modarres HospitalAfsluttetKomplikationer | Billedstyret biopsi | Nyre GlomerulusIran, Islamisk Republik
-
Healthy.io Ltd.Afsluttet
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadUkendtErhvervsmæssig eksponering | Muskuloskeletal sygdomChile
-
Duke UniversityTrukket tilbageAntikoagulation og trombose Point of Care Test (AT-POCT)Forenede Stater